CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

NCT07328503 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

20

Enrollment

NIH

Sponsor class

Conditions

Acute Lymphoblastic Leukemia
B-All

Interventions

BIOLOGICAL: CD22 CAR-transduced T cells
DRUG: Cyclophosphamide
DRUG: Fludarabine

Sponsor

National Cancer Institute (NCI)